Whakaari/White Island: Anatomy of a deadly eruption and the quest to save survivors – Stuff.co.nz

It was a beautiful day for a once-in-a-lifetime adventure. But when disaster struck at Whakaari/White Island, some of thepeople who were there didn't come home. Nikki Macdonald examines how the tragedy unfolded.

2.10pm

At 2.10pm the GNS Science webcam at Whakaari/White Island's crater rim snapsan ant-trail of tourists checking out New Zealand's most active volcano. One minute later, the ever-puffingcone, whose Mori name means the dramatic volcano, blowsits top. There are 47 tourists still on the island, but the world doesn't know that yet.

Near the pier wheretour passengers load and unload, a boat is waiting to leave, to return its day-trippers to Whakatne, 50km away.On board is a group who just 20 minutes earlier were in their hard hats and gas masks, doing that same regular loop to the crater's steamy yellow edge,offered as part of the standard 1hour inner-crater tour.

"No, no, no," a passenger cries out, as they watch the mushrooming cloud of white and black smoke and ash surge from the area they've just left. "Ca commence," a French tourist exclaims it's starting. "Go inside, go inside," a frantic voice calls out.

The beautiful silent shroud turns sinister, rolling across the island.At the pier, about 13 people huddle as the toxic tower rises above their heads. Ash-covered tourists run into the sea.

The Volcanic Air tour helicopter parked on the beach is shunted from its helipad, its rotors bent into spidery legs. That's 1.5 tonnes of metal, carried by the force of the explosion. Its four German passengers are down by the beach. Two passengers and the pilot escape serious harm by jumping into the water. The others suffer burns.

Theash cloud soars to more than 3600mfarenough to see fromsatellites.

Six weeks earlier, Stuff reportedthat the island's sulphurdioxide gas and volcanic tremorshad hit their highest levels since 2016,increasingthe possibility of an eruption. On November 18, GNS raised the volcano's alert level from one to two out of five advising that eruptions of steam, gas, mud and rocks could occur "with little or no warning".

GNS vulcanologist Geoff Kilgoursays rocks and minerals had been slowly clogging the geothermal vents, increasing the pressure, like blowing up a balloon. But like a balloon, you can't predict when it might burst.

White Island Tours' websitesays it operates through the various alert levels, but"there isalways a risk of eruptive activity".

At 2.17pm, police are alerted to the disaster.

MICHAEL SCHADE/AP

Tourists who have just left Whakaari watch helplessly from a boat as ash consumes the island.

2.24pm

Tour guides in navy and white striped T-shirts take inflatables from the tour boat to rescue the ash-caked huddle on the pier. At least five rescuees are in critical condition their skin blistered beneath their clothes from severeburns.

University of Auckland vulcanologistProfessor Shane Croninsays the eruptionwould have released a"violent ejection" of hot blocks and ash, and formed'hurricane-like' currents ofwet ash and coarse particles radiating from the explosion vent. That, and a cloud of "pretty much every nasty gas you can think of".

"These can be deadly in terms of causing impact trauma, burns and respiratory problems," Cronin says.

Lillani Hopkins

Geoff and Lillani Hopkins were on the island minutes before the eruption, and helped tend horribly burnt patients on the boat ride back to Whakatne.

The boat crew plead for doctors there are two. Hamilton pastor Geoff Hopkins and his daughter Lillaniare first aiders and also offer to help.

Lillanitriages the patients attaching red, orange or green tags, to show those most at risk of dying. They cut off the victims' clothes, andreplacethem withtheir own to keep themwarm. They're burnt but cold; in shock, drifting in and out of consciousness. They pourwater on the burns. When the water runsout,Lillaniholds a screaming man's hand and sings.

The Hopkinsesare two of few Kiwis on the tour. Those caught in the blast came from all over the world Australia, Britain, Malaysia, the United States, China.Many came from cruise ship, the Ovation of the Seas, which was docked for theday at Tauranga. Later that afternoon, its 4000-odd passengers listenas the captain announcesone of the ship's tour groups hasbeen caught in a volcanic eruption. He reads a list of passengers asked to report in. It's long. Cruisersanxiously checktheir phones.

At 2.30pm, GNS issues a volcanic alert bulletin, raising the alert level to 4, signifying amoderate volcanic eruption.

WHITE ISLAND FLIGHTS/SUPPLIED

Tourism operator White Island Flights captured this image of the Whakaari/White Island eruption.

2.40pm

Before the dust has settled, rescue efforts begin from the air, with Westpac rescue helicopters, two private helicopters and a Volcanic Air tourist helicopter scrambled to help.

Prime Minister Jacinda Ardern later paystribute to the courage of the pilots who selflessly headed into theeruption's aftermath.

One is pilot Mark Law, of Whakatne helicopter company Khu. He's been flying tourists to Whakaari/White Island for years. When he hearsof the eruption, he doesn'thesitate to fire up the rotors of his Squirrel and make the 20-minute flight to the island.

Michael Schade/AP

Crew from tour boats who were waiting to leave sent inflatables back to the island to rescue those caught in the eruption.

His colleague Jason Hill flies their second chopper. Inside the volcano's crater, the dust and gas are swirling, restricting visibility.

On the ground, they can see distressed people. Some sitting, some lying. Several have horrific injuries. They hear emergency services aren't coming, so they start rescuing patients themselves. The dust is so deep it's like running through talcum powder.

Volcanic Air chief pilot Tim Barrow arrives to help.Between them, they load up 12 patients and get them out, to Whakatne Hospital. They're struggling to breathe, and one of Barrow's charges dies on the way.

CHRISTEL YARDLEY/STUFF

Mark Law was one of three commercial helicopter pilots who courageously flew to the island immediately after the eruption, to evacuate patients.

On board oneWestpachelicopter is Dr Tony Smith. He's St John's clinical director, but also works half time as an intensive care specialist for Auckland Hospital. They have a permanent rescue helicopter crew, and he happens to be the doctor on call.

When the call comes in around 2.30pm, information is sketchy. All they know is there'sbeen an eruption, with multiple casualties. As they flytoward the volcano, the scale of the disaster becomes clearer from information from the ground, but it also becomes visible from the air.

"Even before we went over the Coromandel Peninsula we could see the plume of smoke. It was clear that something big had happened."

AUCKLAND WESTPAC RESCUE HELICOPTER

St John clinical director Tony Smith (left) and a paramedic are seen on White Island after the eruption.

They circle over the crater, looking for a safe landing, checking for life. They find neither they can see people, but only those who haven't made it.

Safety is never black or white, always grey, Smith says. They put down on the beach, near the pier, where they figure the boats can fish them out if they have to flee to the water. Everything is covered in thick yellow sulphurous ash. Every wind gust or rotor swish kicks up a dust cloud. It's like walking around in fog.

They can smell the sulphur through the respirator masks. It's incredibly irritating within minutes eyes and any exposed skin are sore. There are no more survivors to save so they head out, back to Whakatne, where six critically injured evacuees are waiting at the airfield and wharf.

SUPPLIED

This 1.5 tonne tour helicopter was shunted off its helipad by the force of the eruption.

3.26pm

On Whakatne's coast, police cordon off Muriwai Drive, to give emergency services room and privacy to deal with the injured. Casualties are removed on stretchers, covered in survival blankets, some dressed only in their underwear. Manyhave life-threatening burns.

Whakatne Hospital goes into mass casualty response, handlingmore critical patients in 12 hours than it normally gets in 12 months. Five will not make it, but the country doesn't know that yet.

Patients are placed wherever there'sspace in the Emergency Department, in the wards, even in the operating theatres. They need stabilising. Some have lungs so burntthey need ventilators to breathe. Others need anaesthetic to deal with the pain. Medicssend out for catering packs of Gladwrap, to cover the weeping wounds.

ONE NEWS

Police cordoned off Whakatne's Muritai Drive, to give emergency crew room to receive the injured.

Of the 31 patients, 27 have burns to more than 30 per cent of their bodies the normal entry criterionfor the national burns unit at Auckland's Middlemore Hospital. They need to get out of tiny Whakatne Hospital, but Middlemore can't cope with everyone. Smith helps co-ordinate ambulances, helicopters and aircraft to fly the injured to the country's four burns units, at Hutt Hospital, Christchurch, Waikato and Middlemore, and the two next best options Auckland and Tauranga.

Some patients have burns to more than 50 per cent of their bodies. The skin is red and blistered, with pieces falling off. The deepest burns turn the skin white, thick and leathery. Medics will need 1.2 million square centimetres of donor skin to patch all the scorched bodies.

Looking around Whakatne ED, Smith is blown away by the scale of the task ahead.

Lillani Hopkins

The ash cloud soars to more than 3600m - far enough to see from satellites.

"In terms of numbers of patients with very severe injuries, andsubsequent impact on the healthcare system of New Zealand,this is by far and away the biggest event we have ever experienced. Patients with 50 per cent burns will occupy many many many tens of hours of surgical operating and operating theatre time, many weeks of intensive care. These are complex patients that require a lot of complex therapies to get them to survive."

At 3.30pm, theNational Emergency Management Agency issues a national warning for a moderate volcanic eruption, advising people living near the ashfall to close windows and wear a dust mask.

BROOK SABIN

Tourists have been visiting Whakaari/White Island for more than 30 years. (File photo)

3.45pm

Prime Minister Jacinda Ardern gives a press conference saying 100 people are believed to have been on the island, and some are unaccounted for. Reports begin to filter to the public, of at least 20 injured, some critical, and possible deaths

At 4.25pm, GNS drops the volcano's alert level back to 3, warning of eruption hazards near the vent. Experts report there "remains significant uncertainty as to future changes but currently, there are no signs of escalation".

4.59pm

Police issue an update, saying only 50 tourists are now believed to have been on the island during the eruption.That's the only good news of the evening.

Just 90 minutes later, the police National Operation Commander, Deputy Commissioner John Tims, stands in the Beehive theatre and announces one of those rescued from the island has died. More deaths are likely, he says.

He doesn't know how many remain on the island, but it could be up to 27. And authorities have decided it's too dangerous for police and emergency services to go back in.

Ross Giblin

National Police Operation Commander, Deputy Commissioner John Tims, was the bearer of continual bad news.

9pm

Police confirm five people have died. Around the world, desperate friends and relatives begin to post missing persons reports on the Red Cross family links website. Theyare parents and children; husbands and wives; young and old.Their nationalities span the globe.

Some are false alarms a 7-year-old Australian boy is later found safe with family in Whakatne. Others are not.

10.20pm

Ardern and Civil Defence Minister Peeni Henare arrive in Whakatne and head to Whakatne District Council for a briefing.

Two hours later, just after midnight, police deliver a critical blow to hope: nomoresearchand rescue will be attempted tonight, despite "double digit" numbers left on the island. A police Eagle helicopter, rescue helicopter and defence force planes have donerecces, butseen no sign of life.

TOM LEE/STUFF

Prime Minister Jacinda Ardern arrives in Whakatne for a briefing on the situation on White Island on Monday night.

TUESDAY, 10 DECEMBER

Even as eight bodies lie unrecovered and unidentified in their ashen graveyard, the questions begin.

Local man Hayden Marshall-Inman is the first victim to be named one of two White Island Tours staff killed. As a tour guide for more than a decade, he knew the risks, his brother says.But he's angry that red tape is preventing them bringing his brother's body home.

"It smells like Pike River all over again.People from Wellington making decisions for people that go on the island daily who knows the island inside out."

FACEBOOK

Hayden Marshall-Inman.

As Australian Prime Minister Scott Morrison confirmsup to threeof the five dead may be Australian, another 11 are unaccounted for and 13 have been hospitalised, the scale of the diplomatic disaster begins to crystallise.

The dead and injured come from seven countries two from Britain, four from Germany, 24 from Australia, five from New Zealand, two from China, one from Malaysia and nine from the United States.

Stories begin appearing on international media, of their countrymen and women caught in the tragedy. And with them come the question why were they allowed on an active volcano that was known to begetting jumpier?

Supplied

Newly weds Lauren and Matt Urey were on White Island when it erupted. They were taken to hospital with burns. Their condition is unknown.

American honeymooners Lauren and Matthew Ureywere severely burntin the explosion. Lauren's mother Barbara Barham is livid had her daughter known it was risky, she would never have gone, she says.Lauren's father says allowing tourists on to an active volcano is "absurd".

Tourists have been trekking out to the island for more than 30 years, including through the volcano's most active period, from 1975 to 2001, when small eruptions were frequent. It has claimed lives before in 1914, a lahar killed 10sulphur miners asleep in their beds. The only survivor was a tabby cat.

Ray Cas, Australian professor of geoscience at Melbourne's Monash University, has said White Island was "a disaster waiting to happen".

CHRISTEL YARDLEY/STUFF

Flowers and cards have started to be placed at the cordon site for White Island victims.

Whether tourists should have been there at all is a question that must be asked, Ardern later says. At 5pm, police announce they will be asking it, in addition tohealth and safety watchdog WorkSafe.

But for now the focus is on supporting grieving families, and the heroes who went in to help.One survivor will later die in hospital, on Tuesday night, bringing the death toll to eight.

"All incidents like this affect everybody," Tony Smith says. "You are a human being. It's impossible to go to something like this and not be affected ... This will be an incident which will be forever etched in our memories."

Read the original here:
Whakaari/White Island: Anatomy of a deadly eruption and the quest to save survivors - Stuff.co.nz

Did Cristina Yang Ever Have a Healthy Relationship on ‘Grey’s Anatomy’? – Showbiz Cheat Sheet

WhenCristina Yang(Sandra Oh) leaves Greys Anatomy in season 10, fans ugly cry. Many viewers believe herdeparture is harder to watchthan the death ofDerek Shepherd(Patrick Dempsey). So, its not surprising that fans still talk about Cristinas time on the show. The latest debate is over whether she ever had a healthy relationship. Lets take a look at what fans are saying.

During the first season ofGreys Anatomy, Cristina begins dating Preston Burke (Isaiah Washington). Early on in the season, Burke breaks off the relationship because he does not want it to ruin their reputations. When Cristina has a miscarriage, the two get back together.

Burke literally never considers what Cristina wants,wrote one Reddit user. When Cristina wants the relationship kept private, he makes it public without her okay. When they get engaged and she wants to tell Meredith before anyone else knows, he almost immediately goes and tells other people. When she says she wants something small, secular, in a courthouse, he gets into planning a big extravagant church wedding.

The pair are engaged and plan a wedding in under one year. On the day of their marriage, Burke and Cristina have a talk that does not end well. The bride remarks that she thought this was what she wanted, however, that is not good enough for Burke. He wants her to know that she wants to be with him. He promptly leaves the church, packs up his things, and moves out.

Their relationship wasnt healthy at all, added concluded the fan. It was pretty clear from the beginning that Burke held all the power.

Cristina is immediately attracted to Owen Hunt (Kevin McKidd) when he makes a guest appearance on Greys Anatomy. Later, when he returns from Iraq, he and Cristina begin a relationshiponly for it to end when he strangles her in his sleep. He does go to therapy sessions for his PTSD and eventually rekindles the relationship with Cristina.

The pair break-up yet again when Teddy Altman (Kim Raver)and old army friend of Owen scomes to work at the hospital, sparking jealousy issues.

Cristina restores their relationship when Owen is unexpectedly shot during a shooting in the hospital. The two get married suddenly, and Cristinas friends believe Owen is taking advantage of her due to the PTSD she has from the shooting.

I hated his whole army personality thing,wrote one fanabout Owen. I also felt like he was super manipulative in his relationship with Cristina.

Cristina gets pregnant shortly after the shooting but desires to have an abortion. Owen does not agree with her decision and tries to bully her into keeping the baby. Fans find the abortion fight to be one of Owens worst moments.

I think Owen is very similar to Burke, added another Redditor. He loved his idea of Cristina but didnt love her.

Fans feel that Cristinas relationship with Owen and the one with Burke were both destructive.

Fans will agree that throughout Cristinas 10 seasons on Greys Anatomy, Meredith (Ellen Pompeo) was her only thriving relationship. They have each others backs, no matter what the situation.

Although I love Meredith and Christinas practically perfect friendship, I think it was necessary for them to have some struggles with each other in season 10, wroteone viewer on Reddit. I think it made their friendship more realistic and relatable to the audience because we all know what its like to have a little competition and disagreements with close friends. Plus, afterward, they were just as close if not closer than they were before.

The two go through strong arguments with each other, but they work it out amicably.

Derek is the love of my life, but youre my soulmate, Meredith told Cristina in the first episode of season 7.

The twisted sisters are the one genuine relationship that Cristina has on the show that is thriving and strong throughout her time at the hospital. Current episodes of Greys Anatomy still includeCristina via text messageand phone calls with Meredith. You can watch for more Cristina references when the show returns on Jan. 23, 2020.

Go here to see the original:
Did Cristina Yang Ever Have a Healthy Relationship on 'Grey's Anatomy'? - Showbiz Cheat Sheet

Senior Lecturer/Associate Professor in Applied Anatomy job with UNIVERSITY OF BRISTOL | 188877 – Times Higher Education (THE)

Centre for Applied Anatomy

Contract type: Open endedWorking pattern: Full time

Closing date for applications: 12-Jan-2020

We have an exciting opportunity to appoint a new member of academic teaching staff to the Centre for Applied Anatomy at the University of Bristol. The Centre focuses on the excellence of practical applied anatomy teaching which is delivered with clinical and professional relevance.

You will work with the Head of Centre in providing educational direction, leadership and management for the Centre for Applied Anatomy (CAA) and to assist in its continued development. You will also act as the Director of Teaching for CAA.

You may teach across all teaching streams in the Centre for Applied Anatomy (Science, Veterinary, Medical, Dental) and will be expected to contribute substantially to practicals, lectures, seminars and project supervision. As Director of Teaching, you will provide leadership to ensure that the Centres educational offerings are distinctive, innovative, high quality and competitive

For informal enquiries please contact:Michelle Spear; Hos-anat@bristol.ac.uk; 0117 33 17839

We welcome applications from all members of our community and are particularly encouraging those from diverse groups, such as members of the LGBT+ andBAME communities, to join us.

Here is the original post:
Senior Lecturer/Associate Professor in Applied Anatomy job with UNIVERSITY OF BRISTOL | 188877 - Times Higher Education (THE)

Innova Invitro The Place Where Parenting Dreams Come True – Georgia Today

Infertility was always a very serious problem for society, both as a medical and as a social-demographic issue. In an era of late parenting, combined with career growth goals which weakened the institution of family, the hazardous effects of toxic influences of ecology and environmental factors saw infertility becoming not just a personal tragedy but a global problem.

Innova Invitro, established and guided by Dr. Ketevan Osidze who is well-known for as being a doctor with excellent results, is fully dedicated to meeting patients expectations. The clinic has been operating since 2016 and is recognized worldwide as having international standards and high pregnancy rates.

We all know that to be a leading clinic in Tbilisi requires hard work. Please tell us a little more about Innova Invitro.

I am really happy to have such an amazing team. I have 16 years working experience in the field of IVF but my goal was to start with the best possible embryology lab. I chose one of the leaders in the field of IVI, the Valencia Institute of Infertility, as a provider of accreditation and runner of our embryology service. Our Embryology Lab Director Jordan Garcia Ortega is a well-known professional worldwide with amazing experience. I think having such an influential person here had an overall impact on the service and quality in this region. We are proud that several Georgians have been trained by him. We continue to employee embryologists from IVI as the number of patients is growing constantly.

What is main activity of your clinic?

We offer services of any difficulty as we are fully equipped and have the know-how. To performing IVF and ICSI intracytoplasmic sperm injection, we can add genetic tests of embryos PGT-A, PGD, and NIPD tests for pregnancies. Our main activity includes ambulatory treatment and diagnostics of infertility. The clinic has all the necessary means to treat women and men: an external control hormonal lab, referral department of laparoscopy, endocrinology and andrology services, and outstanding specialists with up to date ultrasound and XR machines. We think that only proper diagnosis can ensure a successful medical intervention. Our multidiscipline team of gynaecologists, obstetricians, endocrinologists, therapeutics, and anaesthesiologists care about the well-being and satisfaction of patients and their babies.

We feel special responsibility providing donation and surrogacy services, as it is not only medical intervention. We care very much about the transparency and safety of the process for all parties couples, egg or sperm donors and surrogate mothers. This is an absolutely legal process which is well controlled by the government.

We know that you have very positive feedback from patients. What makes your clinic different from others?

Our priority is high standards of medical service, and an individualized and timely approach to any case with properly planned interventions. We have a special department for international patients to make it easy for them to plan and prepare for surrogacy and donation services. They arrive only at the final stages for the procedure and have to spend only several days in Tbilisi. I have to mention that they usually want to stay longer just as tourists and usually come back for several weeks with friends after the babies are born. I can say that medical tourism is contributing a lot to the rise of tourism activity overall. Timely and planned visits and long-distance services are very important to local customers as well, as a lack of time is a reality for many.

What is main diagnosis of your patients?

It is most commonly infertility due to tubal patency problems post-inflammation or post-surgery. Everyone is concerned about the very fast decline in sperm parameters and subfertility and infertility. Along with genetic errors in the Y chromosome, this situation is connected with ecology, air pollution, chemicals in food, steroid abuse and heavy metals in building materials, possible the harm of Wi-Fi and other urban factors, including stress. We are really glad to see men overcoming the stigma of coming for a check-up and visiting earlier, sometimes even before marriage. Infertility is problem of a couple not of a single individual, so faster diagnosis gives faster results.

What are your plans?

We follow all the advances in reproductive medicine field. We would like to share our experience and expertise with professional society by participating in international research and training programs. As part of social responsibility, we will continue to make efforts to make society more informed and educated about infertility treatment and prevention.

What does partnering with IVI mean for your clinic and what is the priority area of activity for Inova Invitro?

The priority area for Inova Invitro is the comprehensive diagnosis and management of all pathologies of infertility, all the while adhering to international standards pertaining to the treatment procedures. The main focus is on vitro fertilization and donation-surrogacy programs. We are home to personnel of the highest calibre with 15 years working experience in the realm of in vitro fertilization. The collaboration with IVI gives our specialists the opportunity to, along with providing the best standards of treatment, develop an integrated approach that incorporates complex diagnostics and consultation.

What makes patients turn to donation or surrogacy? What do these two procedures entail?

Premature ovarian syndrome, genetic abnormalities, poor quality eggs or embryos are among the conditions that urge us to recommend egg donation. Egg fertilization is carried out in the embryological laboratory by the recipient's partner or donor sperm, then transplanted into the uterine cavity of a "potential mother" under ultrasonography. About 12 days after embryo transfer, a pregnancy test or blood test is performed to determine pregnancy.

In case of infertility, when referring to the surrogacy program, stimulation is provided for the biological mother or the donor, and the fertilized egg is transferred to the surrogate mothers womb. Surrogate mothers have no genetic relationship with the embryos.

What are the root causes of infertility?

Infertility is a sensitive global issue. The causes may range from stress, late marriage, ecology, or the deterioration of male spermogram, among others. Quite often, a delayed visit to a doctor becomes one of the major obstacles.

What do you see as the major priority of Inova Invitro?

Our collaboration with Spain, an indisputable leader in the field, and working in accordance with the standards that they set, has been Invitros major asset. Partnering with IVI is a major advantage in terms of research, results and technical support.

Inova Invitro is a clinic that never fails to adhere to the best of European standards, which is also stressed by its maintenance of an embryological laboratory, headed by Jordan Garcia Ortega, a leading specialist at IVI.

How does your team work towards the clinics common goal?

The success of Inova Invitro almost entirely lies in our team's passion and effort to deliver the latest in state-of-the-art expertise and innovation. IVI specialists are valuable members of our team. Our clinic is home for specialists from all the adjacent fields to fertilization, which is another remarkable asset. One can benefit from all the services he/she needs in the comfort of a single space.

What is the pace of development for the field of reproductive medicine?

The field is developing rapidly; new methods are emerging, such as the so-called "gene modification" or embryonic genetic evaluation. All new discoveries are accessible at our clinic and we apply them strictly in accordance with healthcare licensing.

The field of reproductive medicine is undergoing some outstanding developments in Georgia, as the country's healthcare system actively supports it. Under our state-controlled regulations, the patient receives a safe and comprehensive service within a high quality program. The rights of patients, donors and surrogates (with whom the clinic works in close cooperation) are maximally protected.

Tell us about the improving trends of late.

The newly emerging trend is that an ever-increasing number of men address our clinic.

Even before marriage, the couples conduct research and check on their health. Egg and embryo freezing methods are also becoming popular- all these are vital turning points!

What are your last thoughts or advice for patients?

This century has brought to light that the ecological situation and a stressful backdrop work against us. Even with Wi-Fi, the spermogram concentration is weakened and the indicators are corrupted.

Consequently, there are many things to consider in terms of pregnancy. Timely referral to a doctor will prevent many problems.

09 December 2019 17:47

Continued here:
Innova Invitro The Place Where Parenting Dreams Come True - Georgia Today

Sperm Bank Market by Type and Application to 2015 2021 – Herald Space

Sperm bank is a specialized organization, that collects and stores the sperms collected from human sperm donors for the provision to women who need such sperm to have a pregnancy. Sperm bank also known as cryobank or semen bank, and sperms donated in the bank are known as donor sperm, whereas the process of sperm insertion is known as artificial insemination. It is notable that the pregnancy achieved by using sperms in the sperm bank is similar to natural pregnancy, achieved by sexual intercourse.

For Detailed Insights On Enhancing Your Product Footprint, Request For A Sample Here@https://www.persistencemarketresearch.com/samples/5330

The major mechanism involved in the operation of sperm bank underlies the provision of sperms, donated by sperm donors, to the needy women, who, due to various reasons, such as, physiological problems, widow, age and others, are not able to achieve pregnancy.

Sperm bank forms the formal contract with sperm donors, usually for the period of 6-24 months, during which he has to produce sperms and donate to the bank. Usually, monetary compensation will be offered to sperm donors. Although, a donor can donate his sperms for more than two years, but, due to laws and regulations of various countries and a potential threat of consanguinity, a contract is made for maximum two years only.

A donor produces his sperms in a specialized room, called mens production room. From this, the semen fluid is washed, in order to extract the sperms from other materials present in the semen. In case of frozen storage, a cryoprotectant semen extender is added in the sample. Usually, around 20 vials can be extracted from one sample of semen, collected from a sperm donor. These vials are stored in cryogenically preserved condition, in the liquid nitrogen (N2) tanks. Usually, sperms are stored for the period of around 6 months. However, it can be stored for a longer period of time.

The services offered by sperm bank includes provision of sperms, donors selection, guiding recipient for selection of donor, sex selection of baby, and sales of sperms.

Although, sperm banks play a major role in the women who are not able to achieve pregnancy, due to some controversial issues, such as, use of sperms by lesbian couples and others, government healthcare bodies of various countries imposed strict regulations on the sperm bank. In the U.S., sperm banks are regulated by FDA, and treated as Human Cell or Human Tissue or Human Cell and Tissue (HCT/Ps), in the European Union, it is been regulated by EU Tissue Directive, whereas, in the U.K., it is regulated by Human Fertilization and Embryology Authority.

The global market for sperm banks is expected to increase in steady manner in the forecast period, due to market growth propellers, such as, increased prevalence of women miscarriage, technological innovations in the sperm storage industry, and growing awareness towards this type of pregnancy. Increased miscarriage rate is one of the major drivers that fuels market growth.

According to the study report published by HopeXchange, out of 4.4 million pregnancies carried every year in the U.S., around 1 million pregnancies result into miscarriage. Similarly, due to growing concerns towards such pregnancy that achieved without sexual intercourse is also an important market growth propeller. On the other hand, various governmental regulations, negative mindset towards sperm banks and donor, high cost associated with the operating of sperm bank and limited spread across the various regions of the world are some of the major hurdles in the market growth.

Major players operating in the market includes

Make An Inquiry To Customize This Report @https://www.persistencemarketresearch.com/request-customization/5330

Key geographies evaluated in this report are:

Read this article:
Sperm Bank Market by Type and Application to 2015 2021 - Herald Space

By turning stem cells into brain cells, Aspen Neuroscience hopes to rewind the progress of Parkinson’s disease – FierceBiotech

The idea of a cell therapy for Parkinsons disease starts out simple: Symptoms of the progressive disease are largely driven by the deaths of dopamine-producing neurons found deep within the brain. With lower levels of the neurotransmitter come the characteristic tremors, rigidity and slow movements.

By replacing those lost nerve cells with new dopamine producers, researchers hope to renew the brains connection to the bodys muscles and improve a persons overall motor function.

But in the brain, everything becomes more complicated. On top of the risk of immune system rejection that comes with any kind of living tissue transplant, its important to make sure the implanted cells function correctly and do not pick up any dangerous genetic mutations as they grow.

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

Now, a new company, Aspen Neuroscience, aims to tackle both obstacles at once.

First, the startup hopes to avoid any harmful immune reactions by using a patients own cells as a starting point. Then, Aspen plans to implement a rigorous quality control program employing whole genome sequencing and artificial intelligence to make sure the cells stay in line as theyre processed and readied for the procedure.

And to do it, the San Diego-based company is starting out with $6.5 million in seed money plus an impressive roster of names.

They are led by neurology researcher Howard Federoff, previously vice chancellor for health affairs and CEO of the University of California, Irvine health system as well as the executive dean of medicine at Georgetown University. Hes joined by Aspen co-founder and stem cell scientist Jeanne Loring, founding director and professor emeritus of the Center for Regenerative Medicine at the Scripps Research Institute.

Meanwhile, the seed round was led by Domain Associates and Axon Ventures with additional backing from Alexandria Venture Investments, Arch Venture Partners, OrbiMed and Section 32.

Aspen looks to combine its expertise in stem cell biology, genomics and neurology to offer the first autologous cell therapy for Parkinsons diseasewhile others in the space have pursued allogeneic routes, or therapies derived from donors other than the patient.

The process starts with a culture of the patients skin cells, which are then genetically induced to become pluripotent stem cellsor cells capable of differentiating into any other cell type in the body. These are then chemically nudged further to transform into precursor versions of the dopamine-producing neurons, which are typically found in the midbrain and regions responsible for the movement of limbs.

We can say without any equivocation that we can produce the population of cells necessary to transplant, and in a short enough period of time to have a potential beneficial impact on the evolution of the disease, said Federoff, who has also served as chair of the NIHs Recombinant DNA Advisory Committee and helped lead the U.S. Parkinsons Disease Gene Therapy Study Group.

We envisage that this will set back the clock on patients who have Parkinsons, unlike any other therapy that we know of, he told FierceMedTech in an interview.

The number of cells needed would be much smaller compared to other cell therapies and cancer treatments. The healthy human brain contains only about 200,000 dopamine-producing nerve cells, split between its two hemispheres, while patients with Parkinsons disease have lost about 50% or more of those neurons.

Aspen aims to evaluate two doses: one that aims to replace about 60% to 65% of a persons normal cell complement and another larger treatment, Federoff said.

Those smaller doses, as well as starting with a patients donor cells, help make the treatment safer to produce by requiring fewer steps. Each cycle of cell division and multiplication to increase their numbers carries the risk of introducing genetic mutations.

As the cells are grown, they are consistently evaluated with data-driven techniques pioneered by Lorings laboratory. Using whole genome RNA sequencing, Aspen will match the cells up at every stage with a genetic barcode taken from each patient at the start. This will allow them to look for changes, duplications or deletions in the pluripotent stem cell genome.

If the cells harbor mutations that are cancer drivers, we don't want to put those into people, Loring said. The only way is to check the sequencing before we transplant them.

The cells used in the transplant procedure arent fully grown; as neuron progenitors, they mimic the development steps seen in the brain of a growing fetus after theyre placed in the body as they wire themselves up to other neural structures and begin to form new networks of their own.

We anticipate that they will manufacture and release dopamine in a manner that is consistent with synaptic neurotransmission and the process of communicating from cell-to-cell, said Federoff. They will take up dopamine from synapses when it has done its business, bring it back into the cell, and prepare it for another synaptic release.

These are not just dopamine pumps, theyre real neurons, added Loring. They will genuinely replace the cells that have been lost in every way.

Aspen plans to pursue two courses of therapy, for the two major types of Parkinsons disease. Their lead candidate is for idiopathic, or sporadic Parkinsons, while their second is a CRISPR-edited version of the therapy designed to address one of the diseases most common genetic mutations, linked to about 5% of cases.

This would not only aim to restart dopamine production in this orphan indication, but also restore the damaged enzyme GBA, which is seen as an underlying cause. Federoff and Loring expect their sequencing-based quality check system will also help catch any off-target edits linked to the use of CRISPR-Cas9.

The company has yet to secure permission from the FDA to officially launch clinical trials, but the agency has signed off on Aspens plans to prepare a trial-ready cohort of Parkinsons disease patients in the meantime. This would include the initial stages of recruitment and testing, including the selection of patients capable of having their skin cells made into pluripotent stem cells.

After it receives its go-ahead from the FDA, Aspen plans to hit the ground running,enrolling at least 176 participants in a phase 1/2 study that includes a randomized stage to determine clinical benefits.

View post:
By turning stem cells into brain cells, Aspen Neuroscience hopes to rewind the progress of Parkinson's disease - FierceBiotech

Aspen Neuroscience Launches With $6.5 Million Seed Funding to Advance First-of-its-Kind Personalized Cell Therapy for Parkinson’s Disease – BioSpace

SAN DIEGO, Dec. 12, 2019 /PRNewswire/ -- Aspen Neuroscience, Inc.today announced its launch following a $6.5 million seed round led by Domain Associates and Axon Ventures and including Alexandria Venture Investments, Arch Venture Partners, OrbiMed and Section 32 to develop the first autologous cell therapies for Parkinson's disease. Aspen's proprietary approach was developed by the company's co-founders, Jeanne F. Loring, Ph.D., Professor Emeritus and founding director of the Center for Regenerative Medicine at The Scripps Research Institute, and Andres Bratt-Leal, Ph.D., a former post-doctoral researcher in Dr. Loring's lab. The company was initially supported by Summit for Stem Cell, a founding partner and non-profit organization which provides a variety of services for people with Parkinson's disease. Aspen is led by industry veteran Howard J. Federoff, M.D., Ph.D., as Chief Executive Officer.

Parkinson's disease is characterized by the loss of specific brain cells that make the chemical dopamine. Without dopamine, nerve cells cannot communicate with muscles and people are left with debilitating motor problems. Aspen is focusing on human pluripotent stem cells, cultured cells that can become any cell type in the human body. The company's research is specific to induced pluripotent stem cells (iPSCs), which it develops by taking a skin biopsy from a person with Parkinson's disease and turning the tissue into pluripotent stem cells using genetic engineering. Aspen then differentiates the pluripotent stem cells into dopamine-releasing neurons that can be transplanted into that same person (autologous), thereby restoring the types of neurons lost in Parkinson's disease.

As an autologous cell therapy for Parkinson's disease, Aspen's treatment would eliminate the need for immunosuppression because the neurons are transplanted back into the same patient from which they were generated. The use of immunosuppression is necessary with currently available cell therapies for Parkinson's disease and when transplanting cells from one patient to another (allogeneic) to prevent rejection but can pre-dispose the patient to life-threatening complications including infection and add cost to the patient and health system. Aspen is the only company in the world offering an autologous neuron replacement therapy for Parkinson's disease.

Aspen encompasses a powerful executive leadership team including Dr. Federoff who, in addition to his leadership roles at the UC Irvine Health System, was the Executive Vice President for Health Sciences and the Executive Dean of Medicine at Georgetown University. Dr. Federoff also has significant biotech industry experience including co-founding MedGenesis Therapeutix and Brain Neurotherapy Bio, as well as leading the U.S. Parkinson's Disease Gene Therapy Study Group. The company is also proud to announce the addition of several experienced and well-known members to its leadership team including Edward Wirth, M.D., Ph.D., as Chief Medical Officer.

Dr. Wirth currently serves as the Chief Medical Ofcer for Lineage Cell Therapeutics where he oversees clinical development of its two therapeutic programs for spinal cord injuries and lung cancer. He received his M.D. and Ph.D. from the University of Florida in 1994 and remained to conduct postdoctoral research including leading the University of Florida team that performed the rst human embryonic spinal cord transplant in the U.S. Dr. Wirth went on to serve as the Medical Director for Regenerative Medicine at Geron Corporation where the world's rst clinical trial of human embryonic stem cell (hESC)-derived product occurred which demonstrated initial clinical safety.

Drs. Federoff and Wirth are joined by Dr. Loring, as Chief Scientific Officer; Jay Sial, as Chief Financial Officer; Andres Bratt-Leal, Ph.D., as Vice President of Research and Development; Thorsten Gorba, Ph.D., as Senior Director of Manufacturing and Naveen M. Krishnan, M.D., M.Phil., as Senior Director of Corporate Development.

"Aspen is developing a restorative, disease modifying autologous neuron therapy for people suffering from Parkinson's disease," said Dr. Federoff. "We are fortunate to have such a high-caliber scientific and medical leadership team to make our treatments a reality. Our cell replacement therapy, which originated in the laboratory of Dr. Jeanne Loring and was later supported by Summit for Stem Cell and its President, Ms. Jenifer Raub, has the potential to release dopamine and reconstruct neural networks where no disease-modifying therapies exist."

Aspen's lead product (ANPD001) is currently undergoing investigational new drug (IND)-enabling studies for the treatment of sporadic Parkinson's disease. Aspen is also developing a gene-edited autologous neuron therapy (ANPD002) that is in the research stage and targeted toward familial forms of Parkinson's disease beginning with the most common genetic variant in the gene encoding glucocerebrosidase (GBA). Aspen leverages proprietary machine-learning tools and artificial intelligence to ensure quality control during manufacturing and to deliver a safe and reproducible product for each cell line.

"Aspen's financial backing, combined with its experienced and proven leadership team, positions it well for future success," said Kim P. Kamdar, Ph.D., Partner at Domain Associates, one of Aspen's seed investors. "Domain prides itself on investing in companies that can translate scientific research into innovative medicines and therapies that make a difference in people's lives. We clearly see Aspen as fitting into that category, as it is the only company using a patient's own cells for replacement therapy in Parkinson's disease."

About Aspen Neuroscience

Aspen Neuroscience Inc. is a development stage, private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson's disease. Aspen's therapies are based upon the scientific work of world-renowned stem cell scientist, Dr. Jeanne Loring, who has developed a novel method for autologous neuron replacement. For more information and important updates, please visit http://www.aspenneuroscience.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/aspen-neuroscience-launches-with-6-5-million-seed-funding-to-advance-first-of-its-kind-personalized-cell-therapy-for-parkinsons-disease-300973830.html

SOURCE Aspen Neuroscience

Read the original here:
Aspen Neuroscience Launches With $6.5 Million Seed Funding to Advance First-of-its-Kind Personalized Cell Therapy for Parkinson's Disease - BioSpace

Verge Genomics Announces the Addition of Two Renowned Neuroscience Drug Development Industry Experts to its Advisory Board – PR Web

SAN FRANCISCO (PRWEB) December 11, 2019

Verge Genomics, a drug discovery company developing therapies for neurological diseases by integrating a unique all-in-human genomic platform with machine learning, announced today the appointment of two industry leaders to its scientific advisory board. The new members are Thomas Large, PhD, currently CEO and Co-founder of Blue Oak Pharmaceuticals and formerly of Sunovion and Eli Lilly, and James Summers, PhD, formerly Vice President of Neuroscience Research at AbbVie.

We are excited to welcome these accomplished industry veterans with expertise in discovering and developing therapies to treat neurological diseases to Verges advisory board said Alice Zhang, Co-founder and Chief Executive Officer of Verge Genomics. Drs Large and Summers collective experience will be invaluable as we advance our highly promising drug candidates for ALS and Parkinsons disease toward the clinic.

Thomas Large, PhDDr. Large brings more than 20 years of drug discovery, research and translational medicine experience to Verges scientific board. Currently, he is CEO and Co-Founder of Blue Oak Pharmaceuticals, a start-up integrating systems neurobiology, chemistry and informatics to discover drugs with new mechanisms of action for brain disorders.

Previously, Dr. Large was Senior Vice President, Preclinical Research and Translational Medicine at Sunovion Pharmaceuticals Inc. Under his leadership, the group pioneered a target-agnostic approach for CNS drugs, delivering multiple programs now in clinical development including SEP-363856 for schizophrenia, which was recently designated an FDA Breakthrough Therapy. Prior to Sunovion, Dr. Large was a scientific and group leader at Eli Lilly in neuroscience research, where he led projects that resulted in therapeutic candidates for anxiety, psychosis and pain. During his tenure at Eli Lilly, Dr. Large also managed a group developing innovative approaches for drug targets in the CNS, endocrine and oncology therapeutic areas.

Dr. Large holds a PhD in neurobiology and physiology from Northwestern University and completed a Howard Hughes postdoctoral fellowship at the University of California, San Francisco. Dr. Large previously served as a faculty member of the Department of Neurosciences at Case Western Reserve University Medical School.

James Summers, PhDDr. Summers brings over 30 years of drug discovery and pharmaceutical research management experience to Verges scientific advisory board. Previously, he was Vice President of Neuroscience Research at AbbVie, where he led efforts focused on the discovery of new treatments for Alzheimers and Parkinsons diseases, pain, and psychiatric disorders. Under his leadership, his teams advanced more than twenty compounds into development. He established new research sites in Cambridge, MA and Shanghai, China, was an architect of several strategies that defined the future direction of Abbvies global research organizations, and championed multiple successful out-licensing deals, biotech collaborations and venture investments. He currently serves on the board of directors and as an advisor to several biotechnology companies.Dr. Summers earned his Bachelor of Science degree, summa cum laude, in chemistry from Denison University and his doctorate in organic chemistry from Harvard University.

About Verge GenomicsVerge is focused on developing therapeutics for neurological diseases using human genomics to accelerate drug discovery. Verge has created a proprietary all-in-human platform, generating one of the fields largest and most comprehensive databases of ALS and Parkinsons Disease patient genomic data. The Company is led by experienced computational biologists and drug developers who are successfully advancing therapeutic programs in ALS and Parkinsons disease toward the clinic. For additional information, please visit http://www.vergegenomics.com.

Contactsfor Verge GenomicsShannon Stone, PhD415-854-5500shannon@vergegenomics.com

Share article on social media or email:

See the original post:
Verge Genomics Announces the Addition of Two Renowned Neuroscience Drug Development Industry Experts to its Advisory Board - PR Web

COMPASS Pathways and King’s College London Announce Results From Psilocybin Study In Healthy Volunteers – PRNewswire

LONDON, Dec. 12, 2019 /PRNewswire/ -- COMPASS Pathways, a mental health care company, has reported that its COMP360 (psilocybin) was well-tolerated when administered to healthy adult volunteers with support from specially trained therapists in a randomised placebo-controlled trial by King's College London. The results from the phase I study, including data on safety and the feasibility of simultaneous 1:1 administration, were presented last night at the annual meeting of the American College of Neuropsychopharmacology (ACNP). Psilocybin is an active ingredient in so-called "magic mushrooms."

The study looked at the effects of 10mg and 25mg doses of COMP360, compared with placebo, in 89 healthy volunteers.Doses were administered simultaneously to up to six participants, who then received 1:1 psychological support from an assisting therapist throughout the session, overseen by a lead therapist and study psychiatrist.

Key results:

In 2018 COMPASS receivedFDA Breakthrough Therapydesignation for its programme of psilocybin therapy in treatment-resistant depression. COMPASS is currently running a phase IIb study across Europe and North America, involving 216 patients who suffer with depression that hasn't responded to established medications.

Dr Ekaterina Malievskaia, Chief Innovation Officer and Co-Founder, COMPASS Pathways, said, "This study is part of our overall clinical development programme in treatment-resistant depression; we wanted to look at the safety and tolerability profile of our psilocybin, and to look at the feasibility of a model where up to six 1:1 sessions are held at the same time.We are focused on getting psilocybin therapy safely to as many patients who would benefit from it as possible. We are grateful to the many pioneering research institutions whose work over the years has helped to demonstrate the potential of psilocybin in medicine."

Dr James Rucker, Consultant Psychiatrist and Senior Clinical Lecturer in Psychopharmacology at King's College London's Institute of Psychiatry, Psychology & Neuroscience, and lead investigator of the study, said,"This is the largest controlled study of psilocybin to date. The results of the study are clinically reassuring and support further development of psilocybin as a treatment for patients with mental health problems that haven't improved with conventional therapy, such as treatment resistant depression."

About this phase I placebo-controlled trial of COMP360 in healthy volunteers

In this double-blind, placebo-controlled study, 89 healthy volunteers were randomised in a 1:1:1 ratio to receive 10mg COMP360 (n=30), 25mg COMP360 (n=30), or placebo (n=29), with 1:1 support from a trained assisting therapist during a session lasting about six hours. In total, 25 dosing sessions were completed, with up to six participants per session. The study involved a 12 week follow-up period.

About COMPASS Pathways

COMPASS Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. We are developing psilocybin therapy through a late-stage clinical trial in Europe and North America for patients with treatment-resistant depression. COMP360 is an investigational psilocybin formulation developed and produced by COMPASS Pathways.

We think differently about mental health so you can too. http://www.compasspathways.com

About King's College London and the Institute of Psychiatry, Psychology & Neuroscience

King's College London is one of the top 10 UK universities in the world (QS World University Rankings, 2018/19) and among the oldest in England. King's has more than 31,000 students (including more than 12,800 postgraduates) from some 150 countries worldwide, and some 8,500 staff.

The Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London is the premier centre for mental health and related neurosciences research in Europe. It produces more highly cited publications in psychiatry and mental health than any other university in the world (Scopus, 2016), with 31 of the most highly cited scientists in this field. World-leading research from the IoPPN has made, and continues to make, an impact on how we understand, prevent and treat mental illness and other conditions that affect the brain.

https://www.kcl.ac.uk/ioppn

@KingsIoPPN

Logo - https://mma.prnewswire.com/media/733890/COMPASS_Pathways_Logo.jpg

Enquiries:

Tracy Cheung, tracy@compasspathways.com, +44 (0)796-630-9024

Amy Lawrence, amy@compasspathways.com, +44 (0)781-377-7919

SOURCE COMPASS Pathways

Continue reading here:
COMPASS Pathways and King's College London Announce Results From Psilocybin Study In Healthy Volunteers - PRNewswire

Virtual avatar reveals what the brain likes to see – Baylor College of Medicine News

Opening the eyes immediately provides a visual perception of the world and it seems so easy. But the process that starts with photons stimulating the retina and ends with seeing is far from simple. The brains fundamental task in seeing is to reconstruct relevant information about the world from the light that enters the eyes. Because this process is rather complex, nerve cells in the brain neurons also react to images in complex ways.

Experimental approaches to characterize the responses of neurons to images have proven challenging in part because the number of possible images is endless. In the past, seminal insights often resulted from stimuli that neurons in the brain liked. Finding them relied on the intuition of the scientists and a good portion of luck, said senior author Dr. Andreas Tolias, professor and Brown Foundation Endowed Chair of Neuroscience at Baylor College of Medicine.

We want to understand how vision works. We approached this study by developing an artificial neural network that predicts the neural activity produced when an animal looks at images. If we can build a virtual avatar of the visual system, we can perform essentially unlimited experiments on it. Then we can go back and test in real brains with a method we named inception loops, said first author Dr. Edgar Y. Walker, former graduate student in the Tolias lab and now a postdoctoral scientist at University of Tbingen and Baylor.

To make the avatar learn how neurons respond, the researchers first recorded a large amount of brain activity using a mesoscope, a recently developed large scale functional imaging microscope. First, the researchers showed mice about 5,000 natural images and recorded the neural activity from thousands of neurons as they were seeing the images. Then, they used these images and the corresponding recordings of brain activity to train a deep artificial neural network to mimic how real neurons responded to visual stimuli.

To test whether the network had indeed learned to predict neural responses to visual images like a living mouse brain would do, we showed the network images it had not seen during learning and saw that it predicted the biological neuronal responses with high accuracy, said co-first author Dr. Fabian Sinz, adjunct assistant professor of neuroscience at Baylor and group leader at the University of Tbingen.

Experimenting with these networks revealed some aspects of vision we didnt expect, said Tolias, founder and director of the Center for Neuroscience and Artificial Intelligence at Baylor.

For instance, we found that the optimal stimulus for some neurons in the early stages of processing in the neocortex were checkerboards, or sharp corners as opposed to simple edges which is what we would have expected according to the current dogma in the field.

We think that this framework of fitting highly accurate artificial neural networks, performing computational experiments on them, and verifying the resulting predictions in physiological experiments can be used to investigate how neurons represent information throughout the brain. This will eventually give us a better idea of how the complex neurophysiological processes in the brain allow us to see, Sinz said.

Find all the details of this study in the journal Nature Neuroscience.

Other contributors to this work include Erick Cobos, Taliah Muhammad, Emmanouil Froudarakis, Paul G. Fahey, Alexander S. Ecker, Jacob Reimer and Xaq Pitkow.

Follow this link to find the complete list of author affiliations and financial support for this project.

By Ana Mara Rodrguez, Ph.D.

The rest is here:
Virtual avatar reveals what the brain likes to see - Baylor College of Medicine News